A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

NCT03942042 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Pustular Psoriasis
Erythrodermic Psoriasis

Interventions

DRUG: Ixekizumab

Sponsor

Eli Lilly and Company